Institution

Universitair Ziekenhuis Leuven

Leuven, BelgiumWebsite

Also known as: UZ Leuven

765running trials
367closed trials
50,803publications (OpenAlex)

Running trials

Not yet recruiting
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT07335562· Phase 3· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source
Not yet recruiting
A study to learn how dapirolizumab pegol transfers to babies from pregnant mothers with active systemic lupus erythematosus
2025-524595-37-00· Phase 1· UCB Biopharma· Source
Not yet recruiting
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
NCT07915219· Phase 3· Boehringer Ingelheim· Source
Not yet recruiting
Within-Session Repeatability of EUS-Guided Portal Pressure Gradient Measurement
NCT07877298· University Hospital Muenster· Source
Not yet recruiting
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
NCT07291102· Phase 3· Nationwide Children's Hospital· Source
Not yet recruiting
The CORE Platform Trial
NCT07892976· Copenhagen Trial Unit, Center for Clinical Intervention Research· Source
Not yet recruiting
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
NCT07738887· Phase 2· The Lymphoma Academic Research Organisation· Source
Not yet recruiting
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408· Phase 3· Bristol-Myers Squibb· Source
Not yet recruiting
Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis
2025-523400-72-00· Phase 2· Vertex Pharmaceuticals Inc.· Source
Not yet recruiting
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015· Phase 3· Boehringer Ingelheim· Source
Not yet recruiting
Assessment of self-perceived stress and repetitive behaviors after six weeks of daily intranasal oxytocin administration versus placebo: a randomised, multicentre, parallel group pragmatic trial in 210 men and women with autism
2025-524797-42-00· Phase 3· UZ Leuven· Source
Not yet recruiting
A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis
2026-526404-71-00· Phase 2· Agomab Spain S.L.U.· Source
Recruiting
Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
NCT07781657· Phase 2· Hoffmann-La Roche· Source
Not yet recruiting
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
NCT07919405· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
2024-518365-10-00· Phase 3· F. Hoffmann-La Roche AG· Source
Not yet recruiting
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
NCT07116473· Phase 3· Eidos Therapeutics, a BridgeBio company· Source
Recruiting
A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease
2026-525197-19-00· Phase 2· Agomab Spain S.L.U.· Source
Recruiting
Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression
2025-524641-27-00· Phase 3· K-Group Beta Inc.· Source
Recruiting
STRATHEP: AI-Driven Treatment Stratification for Advanced Hepatocellular Carcinoma
NCT07863258· Universitaire Ziekenhuizen KU Leuven· Source
Recruiting
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).
2026-526139-20-00· Phase 3· Kardigan Inc.· Source
Recruiting
Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
2025-524928-21-00· Phase 3· Revolution Medicines Inc.· Source
Recruiting
This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization
NCT07587658· Phase 4· Regeneron Pharmaceuticals· Source
Not yet recruiting
Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
2025-524969-24-00· Phase 3· Revolution Medicines Inc.· Source
Not yet recruiting
Prospective diagnostic performance of PET/CT using the novel fibroblast imaging tracer [18F]-AlF-FAPI-74 versus power doppler ultrasound in psoriasis patients with arthralgia: early detection of psoriatic arthritis
2026-526942-29-00· Phase 2/3· UZ Leuven· Source
Recruiting
Prospective Trial of [18F]AlF-FAPI-74 for PET Imaging of Fibroblast Activation Protein in Patients With Endometriosis
NCT07876648· Phase 2· Universitaire Ziekenhuizen KU Leuven· Source
Recruiting
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
NCT07441200· Phase 2· NS Pharma, Inc.· Source
Recruiting
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
NCT07768189· Phase 3· Corbus Pharmaceuticals Inc.· Source
Recruiting
ENDO-REAL: Endometriosis and Reproductive Enhancement with Letrozole
2025-524995-53-00· Phase 4· UZ Brussel· Source
Recruiting
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
NCT07817875· Phase 3· Eli Lilly and Company· Source
Recruiting
Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)
2026-525489-23-00· Phase 3· Amgen Inc.· Source
Recruiting
Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation
NCT07753148· Phase 1· Regeneron Pharmaceuticals· Source
Recruiting
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
NCT07701941· Phase 1/2· Daiichi Sankyo· Source
Recruiting
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
NCT07811193· Phase 2· Vividion Therapeutics, Inc.· Source
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· Phase 3· Takeda· Source
Not yet recruiting
Rehabilitation Through Individualized Support and Exercise
NCT07857096· Universitaire Ziekenhuizen KU Leuven· Source
Recruiting
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
NCT07623200· Phase 3· Incyte Corporation· Source
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
2025-525009-18-00· Phase 3· Incyte Corp.· Source
Recruiting
A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation
NCT07625215· Phase 2· Bayer· Source
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
NCT07587242· Phase 3· Avidity Biosciences, Inc.· Source
Recruiting
Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation
NCT07405671· Phase 4· Universitaire Ziekenhuizen KU Leuven· Source
Not yet recruiting
Targeted Muscle Activation During Strength Training for Children With CP
NCT07800221· Universitaire Ziekenhuizen KU Leuven· Source
Recruiting
A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus
NCT07630714· Phase 2· AstraZeneca· Source
Recruiting
A neuropsychobiological approach to optimize patient selection for GLP-1-based pharmacotherapy for weight management across the binge eating spectrum
2026-526016-36-00· Phase 4· UZ Leuven· Source
Recruiting
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
NCT07771465· Phase 3· Kardigan, Inc.· Source
Recruiting
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
NCT07737743· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
A clinical trial of MK-8210 in healthy participants (MK-8210-001)
2026-527022-13-00· Phase 1· Merck Sharp & Dohme LLC· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
2025-525105-20-00· Phase 1/2· AbbVie Deutschland GmbH & Co. KG· Source
Recruiting
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
NCT07566052· Phase 3· Astellas Pharma Global Development, Inc.· Source
Not yet recruiting
A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)
NCT07760818· Phase 2· argenx· Source
Recruiting
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
NCT07626411· Phase 3· Regeneron Pharmaceuticals· Source

Showing 50 of 765.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Lung cancer38 recruiting
Childhood cancers35 recruiting
Ovarian cancer28 recruiting
Colorectal cancer26 recruiting
Crohn's disease25 recruiting
Metastatic breast cancer19 recruiting
Pancreatic cancer16 recruiting
Ulcerative colitis16 recruiting
Endometrial cancer14 recruiting
Prostate cancer14 recruiting
Gastric and oesophageal cancer13 recruiting
High blood pressure13 recruiting
Acute myeloid leukaemia12 recruiting
Coronary artery disease11 recruiting
Obesity11 recruiting
ALS (motor neurone disease)10 recruiting
Chronic lymphocytic leukaemia10 recruiting
Duchenne muscular dystrophy10 recruiting
Head and neck cancer10 recruiting
Parkinson disease10 recruiting
Stroke10 recruiting
Atrial fibrillation9 recruiting
Heart failure9 recruiting
Liver and biliary tract cancer9 recruiting
Multiple myeloma9 recruiting
Alzheimer disease8 recruiting
Melanoma8 recruiting
Rheumatoid arthritis8 recruiting
Bladder cancer7 recruiting
Cerebral palsy7 recruiting
Idiopathic pulmonary fibrosis7 recruiting
Lupus (SLE)7 recruiting
Pulmonary arterial hypertension7 recruiting
COPD6 recruiting
Myelodysplastic syndromes6 recruiting
Psoriasis6 recruiting
Sarcoma6 recruiting
Triple-negative breast cancer6 recruiting
Type 1 diabetes6 recruiting
Acute lymphoblastic leukaemia5 recruiting
Amyloidosis5 recruiting
Kidney cancer5 recruiting
Myasthenia gravis5 recruiting
Myeloproliferative neoplasms5 recruiting
Type 2 diabetes5 recruiting
Cervical cancer4 recruiting
Chronic kidney disease4 recruiting
Dilated cardiomyopathy4 recruiting
Glioblastoma4 recruiting
Lewy body dementia4 recruiting
Neuroendocrine tumours4 recruiting
Osteoarthritis4 recruiting
Peripheral artery disease4 recruiting
Psoriatic arthritis4 recruiting
Ankylosing spondylitis3 recruiting
Autism3 recruiting
Chronic myeloid leukaemia3 recruiting
CIDP (chronic inflammatory demyelinating polyneuropathy)3 recruiting
Cystic fibrosis3 recruiting
Diffuse large B-cell lymphoma3 recruiting
Endometriosis3 recruiting
Haemophilia3 recruiting
Hodgkin lymphoma3 recruiting
Huntington's disease3 recruiting
Irritable bowel syndrome3 recruiting
Liver cirrhosis3 recruiting
Polycystic kidney disease3 recruiting
Sjögren's disease3 recruiting
Systemic sclerosis (scleroderma)3 recruiting
Aortic stenosis2 recruiting
Bronchiectasis2 recruiting
Dermatomyositis and polymyositis (myositis)2 recruiting
Epilepsy2 recruiting
Fabry disease2 recruiting
Frontotemporal dementia2 recruiting
Hidradenitis suppurativa2 recruiting
Multiple system atrophy2 recruiting
Neuroblastoma2 recruiting
Pompe disease2 recruiting
Primary biliary cholangitis2 recruiting
Asthma1 recruiting
Barrett's oesophagus1 recruiting
Bipolar disorder1 recruiting
Coeliac disease1 recruiting
Congenital heart disease1 recruiting
Cytomegalovirus infection1 recruiting
Depression1 recruiting
Familial hypercholesterolaemia1 recruiting
Fatty liver disease (MASLD/MASH)1 recruiting
Follicular lymphoma1 recruiting
Gastroparesis1 recruiting
Glaucoma1 recruiting
Hearing loss1 recruiting
HIV1 recruiting
IgA nephropathy1 recruiting
Macular degeneration1 recruiting
Meningioma1 recruiting
Multiple sclerosis1 recruiting
Myocarditis1 recruiting
Narcolepsy1 recruiting
Obstructive sleep apnoea1 recruiting
Osteoporosis1 recruiting
Schizophrenia1 recruiting
Sickle cell disease1 recruiting
Spinal cord injury1 recruiting
Spinal muscular atrophy1 recruiting
Ventricular tachycardia1 recruiting

Closed trials

Terminated
HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
NCT06595563· Phase 2· Jules Bordet Institute· Source
Not yet recruiting
HOVON 168:Study on epcoritamab in frail patients with diffuse large B-Cell lymphoma (DLBCL) who have not been treated before
2025-524230-25-00· Phase 2· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source
Completed
A clinical trial of MK-1824 in healthy participants (MK-1824-001)
2026-525748-14-00· Phase 1· Merck Sharp & Dohme LLC· Source
Completed
A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative colitis
NCT07222189· Phase 2· Sanofi-Aventis Recherche & Developpement· Source
Completed
A Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with NSCLC
2025-522867-13-00· Phase 2· Merus B.V.· Source
Completed
An Open-Label Extension Study for Participants with PAH Who Have Previously Participated in a Clinical Trial with PF-07868489
2025-521155-23-00· Phase 2· Pfizer Inc.· Source
Completed
A Phase 1 Study of ATV-1601, in Patients with Advanced Cancer that have AKT1 E17K Mutations
2025-521480-12-00· Phase 1· Atavistik Bio Inc.· Source
Recruiting
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
NCT07048262· Phase 2· CSL Behring· Source
Recruiting
A Phase 2a Study of the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis
2024-520201-39-00· Phase 2· Odyssey Therapeutics Inc.· Source
Terminated
A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy
NCT06987968· Phase 2· Genfit· Source
Completed
Implementation of the MOX Activity Monitor in Hospitalized Geriatric Rehabilitation
NCT07124247· KU Leuven· Source
Completed
A Study With CIT-013 in RA Patients
NCT06567470· Phase 2· Citryll BV· Source
Completed
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
NCT06926660· Phase 2· Boehringer Ingelheim· Source
Recruiting
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
NCT06699849· Phase 2· CSL Behring· Source
Completed
A study to investigate efficacy and safety of SAR441566 in patients with ulcerative colitis
NCT06867094· Phase 2· Sanofi-Aventis Recherche & Developpement· Source
Completed
A Phase 2b Study to Assess the Safety and tolerability of Batoclimab in Patients with CIDP
2024-518364-12-00· Phase 2· Immunovant Sciences GmbH· Source
Completed
A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on their Biomarker Status
2024-511239-91-00· Phase 2· F. Hoffmann-La Roche AG· Source
Completed
A trial to learn how safe AZD0022 is, how well it works, and how it moves throughout the body over time in adults with tumors that have a KRAS-G12D mutation, when given alone and with other cancer drugs
NCT06599502· Phase 1/2· AstraZeneca AB· Source
Completed
A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY)
NCT06684847· Phase 3· Argenx· Source
Completed
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis
2023-507771-22-01· Phase 3· Intercept Pharmaceuticals Inc.· Source
Active, not recruiting
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
NCT06840483· Phase 2· BicycleTx Limited· Source
Active, not recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920· Phase 3· Novartis Pharmaceuticals· Source
Completed
A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapy
2023-508998-85-00· Phase 1· Boehringer Ingelheim International GmbH· Source
Active, not recruiting
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
NCT06632951· Phase 2· AbbVie· Source
Active, not recruiting
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522· Phase 2· Amgen· Source
Completed
A clinical study of MK-2420 in healthy men (MK-2420-003)
2024-518104-47-00· Phase 1· Merck Sharp & Dohme LLC· Source
Completed
Smart MDI Study (CIP343)
NCT06645834· Medtronic MiniMed, Inc.· Source
Completed
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
NCT06433219· Phase 2· EMD Serono Research & Development Institute, Inc.· Source
Completed
A safety and efficacy study of ARGX-119 in adult patients with Amyotrophic Lateral Sclerosis (ALS) (reALiSe)
NCT06441682· Phase 2· Argenx· Source
Active, not recruiting
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.
NCT06321601· Phase 3· Amgen· Source
Completed
A Study of TAK-861 in People With Narcolepsy Type 1
NCT06505031· Phase 3· Takeda· Source
Withdrawn
3rd Generation Resorbable Magnesium Scaffolds vs Biodegradable Polymer Stents in NSTE/ACS
NCT06409117· Konstantinos Toutouzas· Source
Completed
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa
2024-511363-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Active, not recruiting
Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome
NCT06315751· Phase 2· Noema Pharma AG· Source
Completed
Safety and Efficacy of NMD670 in Adult Patients with Type 1 and Type 2 Charcot-Marie-Tooth Disease
2023-507892-23-00· Phase 2· NMD Pharma A/S· Source
Active, not recruiting
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142· Phase 3· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Source
Completed
A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease
NCT06522997· Phase 2· Bayer· Source
Completed
A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction
2023-508736-62-00· Phase 2· Cardurion Pharmaceuticals Inc.· Source
Active, not recruiting
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
NCT06544616· Phase 2· Janssen Pharmaceutica N.V., Belgium· Source
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575· Phase 3· Jazz Pharmaceuticals· Source
Recruiting
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients with Myasthenia Gravis
2023-507539-40-00· Phase 2· NMD Pharma A/S· Source
Completed
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)
2023-506185-31-00· Phase 2/3· Pliant Therapeutics Inc.· Source
Active, not recruiting
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
NCT06456580· Phase 3· Vor Biopharma· Source
Completed
Add-on Clioquinol in drug-resistant epilepsy: an exploratory study
2024-511388-27-04· Phase 2· UZ Leuven· Source
Active, not recruiting
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128· Phase 3· Sanofi· Source
Terminated
To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate
NCT06488911· Phase 3· Intercept Pharmaceuticals· Source
Completed
Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction
2023-506210-40-00· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
A Retrospective Chart Review Study of Patients With CLAD-BOS Post Lung Transplantation
NCT06503770· Zambon SpA· Source
Completed
Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar )
NCT06341712· Phase 2· Ipsen Innovation· Source
Active, not recruiting
Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.
NCT06359002· Phase 1· Byondis B.V.· Source

Showing 50 of 367.

Registry name variants (116)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

UZ Leuven
Leuven, 3000
1,032 trials
Universitair Ziekenhuis Leuven
Leuven, 3000
27 trials
Universitair Ziekenhuis Leuven - Campus Gasthuisberg
Leuven, 3000
19 trials
Universitair Ziekenhuis (Uz) Leuven
Leuven, 03000
9 trials
UZ Leuven - Endocrinology
Leuven, 3000
4 trials
UZ Leuven - Gasthuisberg Campus
Leuven, 3000
3 trials
- NCT07768189A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
  Contact: Clinical Study Coordinator
- NCT06522737A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
  Contact: Koen Debackere (principal investigator)
- NCT03283085A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
UZ Leuven
Pellenberg, 3212
2 trials
- NCT03631706M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
- NCT03372278PMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty
UZ Leuven - Hart en Vaatziekten
Leuven, 3000
2 trials
- NCT04560998A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes
- NCT03745924A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN
UZ Leuven - Kindergeneeskunde
Leuven, 3000
2 trials
- NCT05685238A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
- NCT05053139A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors
UZ Leuven/KU Leuven
Leuven, 3000
2 trials
- NCT07413614The Acute Effect of Exercise Type And Timing on Ambulatory Blood Pressure and Intra-Ocular Pressure in Individuals With Glaucoma (The ACHIEVE-project).
  Contact: Marie Renier, MSc
- NCT07666113Blood-based Biomarkers for Alzheimer's Disease at the Primary Care Level.
  Contact: Serafien D'hooge, MD
UZ Leuven - PPDS
Leuven, 3000
2 trials
- NCT07294170ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
  Contact: Kristl Claeys, MD
- NCT06243731A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
  Contact: Dirk Kuypers (principal investigator)
0560036 - Universitair Ziekenhuis Leuven
Leuven, 3000
1 trial
- NCT03473223Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
KU/UZ Leuven
Leuven, 3000
1 trial
- NCT07211750Integrated Care for Older Adults With Major Depression and Physical Multimorbidity - The I-CONNECT
  Contact: Louise de Almeida Ferreira Fonseca
Universitaire Ziekenhuizen Leuven (UZ Leuven)
Leuven, B-3000
1 trial
- NCT06503770A Retrospective Chart Review Study of Patients With CLAD-BOS Post Lung Transplantation
Universitaire Ziekenhuizen Leuven/ UZ Leuven/ UZL
Leuven, 3000
1 trial
- NCT06634628iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009
  Contact: Wim Vandenberghe, MD, PhD
Universitaire Ziekenhuizen (Uz) Leuven - Campus Gasthuisberg - Multidisciplinair Borstcentrum (Multidisciplinary Breast Center) (Mbc)
Leuven, 03000
1 trial
- NCT05563220Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg
Leuven, 3000
1 trial
- NCT03025308Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis
Universitair Ziekenhuis Leuven (Adults and Pediatrics)
Leuven, Flemish Brabant 3000
1 trial
- NCT03394365A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
  Contact: Data Protection Officer
Universitair Ziekenhuis Leuven - Gasthuisberg
Leuven, 3000
1 trial
- NCT02675231A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
Universitair Ziekenhuis Leuven /ID# 124980
Leuven, Vlaams-Brabant 3000
1 trial
- NCT02163694A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
Universitair Ziekenhuis Leuven /ID# 127984
Leuven, Vlaams-Brabant 3000
1 trial
- NCT01848561A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Universitair Ziekenhuis Leuven /ID# 215684
Leuven, Vlaams-Brabant 3000
1 trial
- NCT04379050Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
Universitair Ziekenhuis Leuven /ID# 218806
Leuven, Vlaams-Brabant 3000
1 trial
- NCT04472598Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
Universitair Ziekenhuis Leuven /ID# 240312
Leuven, Vlaams-Brabant 3000
1 trial
- NCT03891446Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
Universitair Ziekenhuis Leuven /ID# 246461
Leuven, Vlaams-Brabant 3000
1 trial
- NCT05618028Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
Universitair Ziekenhuis Leuven /ID# 246671
Leuven, Vlaams-Brabant 3000
1 trial
- NCT06508658A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Universitair Ziekenhuis Leuven /ID# 251399
Leuven, Vlaams-Brabant 3000
1 trial
- NCT05601882A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Universitair Ziekenhuis Leuven /ID# 252457
Leuven, Vlaams-Brabant 3000
1 trial
- NCT05959070An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)
Universitair Ziekenhuis Leuven /ID# 269736
Leuven, Vlaams-Brabant 3000
1 trial
- NCT05041257Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers
Universitair Ziekenhuis Leuven /ID# 275586
Leuven, Vlaams-Brabant 3000
1 trial
- NCT07005102A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Universitair Ziekenhuis Leuven /ID# 277350
Leuven, Vlaams-Brabant 3000
1 trial
- NCT06682988A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Universitair Ziekenhuis Leuven /ID# 279439
Leuven, Vlaams-Brabant 3000
1 trial
- NCT07382440A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium
  Contact: Clementine Semanaz
UZ Leuven, campus Pellenberg
Pellenberg, 3212
1 trial
- NCT07124247Implementation of the MOX Activity Monitor in Hospitalized Geriatric Rehabilitation
UZ Leuven - Department of Gastroenterology and Hepatology
Leuven
1 trial
- NCT04882007Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis
UZ Leuven - Digestive oncology
Leuven, Flemish Brabant 3000
1 trial
- NCT07811193A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
UZ Leuven /ID# 272781
Leuven, Vlaams-Brabant 3000
1 trial
- NCT06764693An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
  Contact: Shari Chapman
UZ Leuven, Neurologie Herestraat 49
Leuven, 3000
1 trial
- NCT04408625Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
UZ Leuven, Radiotherapy & Oncology
Leuven
1 trial
- NCT04459715A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
UZ Leuven (Site 0161)
Leuven, Vlaams-Brabant 3000
1 trial
- NCT04210115Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
UZ Leuven (Site 0205)
Leuven, Vlaams-Brabant 3000
1 trial
- NCT04003636Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
UZ Leuven (Site 0377)
Leuven, Vlaams-Brabant 3000
1 trial
- NCT03867084Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
UZ Leuven (Site 1004)
Leuven, Vlaams-Brabant 3000
1 trial
- NCT04662710Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
UZ Leuven (Site 1101)
Leuven, Vlaams-Brabant 3000
1 trial
- NCT04586231A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
UZ Leuven (Site 1300)
Leuven, Vlaams-Brabant 3000
1 trial
- NCT05446870Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
UZ Leuven (Universitair Ziekenhuis Leuven)
Leuven, 3000
1 trial
- NCT06713135A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy
0560048 - Universitair Ziekenhuis (UZ) Leuven
Leuven, 3000
0560056 - Universitair Ziekenhuis Leuven
Leuven, 3000
Universitair Ziekenhuis Leuven /ID# 150468
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 157407
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 170829
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 200031
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 208209
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 215006
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 218905
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 223901
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 225951
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 242384
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 247780
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 248598
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 251185
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 254089
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 255098
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 257079
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 258226
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 260304
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 261302
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 261740
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 263098
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 265519
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 268914
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 269308
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 269370
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 269957
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 272382
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 276316
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 276874
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 278668
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven /ID# 279330
Leuven, Vlaams-Brabant 3000
Universitair Ziekenhuis Leuven (UZ Leuven) - Campus Gasthuisberg
Leuven, 3000
Universitair Ziekenhuis (UZ) Leuven - Campus Gasthuisberg
Leuven, Flemish Brabant 3000
UZ Leuven
Flemish Brabant, 3000
UZ Leuven
Gasthuisberg
UZ Leuven - Campus Gasthuisberg - Nuclear Medicine
Leuven, Flemish Brabant 3000
UZ Leuven - Campus Gasthuisberg (Site 1401)
Leuven, Vlaams-Brabant 3000
UZ Leuven - Centrum voor Moleculaire en Vasculaire Biologie
Leuven, 3000
UZ Leuven - E507 Studies IBD tav Tine Hermans
Leuven, 3000
UZ Leuven - Geheugenkliniek
Leuven, 3000
UZ Leuven - Internal Medicine
Leuven, 03000
UZ Leuven / Nephrology
Leuven, 3000
UZ Leuven - Neurochirurgie Campus Gasthuisberg
Leuven
UZ Leuven - Neurology department
Leuven, 3000
UZ Leuven - Pediatric Cardiology
Leuven, Flemish Brabant 3000
UZ Leuven (Site 0101)
Leuven, Vlaams-Brabant 3000
UZ Leuven (Site 0221)
Leuven, Vlaams-Brabant 3000
UZ Leuven (Site 0252)
Leuven, Vlaams-Brabant 3000
UZ Leuven (Site 0300)
Leuven, Vlaams-Brabant 3000
UZ Leuven (Site 0301)
Leuven, Vlaams-Brabant 3000
UZ Leuven (Site 0303)
Leuven, Vlaams-Brabant 3000
UZ Leuven (Site 0354)
Leuven, Vlaams-Brabant 3000
UZ Leuven (Site 0361)
Leuven, Vlaams-Brabant 3000
UZ Leuven (Site 0401)
Leuven, Vlaams-Brabant 3000
UZ Leuven (Site 0483)
Leuven, Vlaams-Brabant 3000
UZ Leuven (Site 0600)
Leuven, Vlaams-Brabant 3000
UZ Leuven (Site 0601)
Leuven, Vlaams-Brabant 3000
UZ Leuven (Site 0700)
Leuven, Vlaams-Brabant 3000
UZ Leuven (Site 1002)
Leuven, Vlaams-Brabant 3000
UZ Leuven (Site 1301)
Leuven, Vlaams-Brabant 3000
UZ Leuven (Site 1401)
Leuven, Vlaams-Brabant 3000
UZ Leuven (Site 2001)
Leuven, Vlaams-Brabant 3000
UZ Leuven (Site 2040)
Leuven, Vlaams-Brabant 3000
UZ Leuven (Site 3000)
Leuven, Vlaams-Brabant 3000
UZ Leuven (Site 3200)
Leuven, Antwerpen 3000
UZ Leuven (Site 3400)
Leuven, Vlaams-Brabant 3000
UZ Leuven (Site 4402)
Leuven, Vlaams-Brabant 3000
UZ Leuven (Univ Ziekenhuis Leuven)
Leuven, 3000
UZ Leuven, UZ Leuven Campus Gasthuisberg, Herestraat 49
Leuven, 3000

Conditions

Diseases this institution publishes on or runs trials for.

Ulcerative colitis84 works · 53 trials
Crohn's disease80 works · 44 trials
Ovarian cancer35 works · 57 trials
Type 1 diabetes33 works · 13 trials
Bronchiectasis30 works · 7 trials
Glaucoma27 works · 4 trials
ALS (motor neurone disease)25 works · 20 trials
COPD24 works · 14 trials
Cerebral palsy23 works · 10 trials
Congenital heart disease19 works · 2 trials
Idiopathic pulmonary fibrosis18 works · 17 trials
Endometrial cancer18 works · 27 trials
Frontotemporal dementia16 works · 7 trials
Cystic fibrosis16 works · 9 trials
Cytomegalovirus infection12 works · 4 trials
Head and neck cancer12 works · 18 trials
Neuroendocrine tumours11 works · 6 trials
Ventricular tachycardia11 works · 1 trial
Childhood cancers10 works · 53 trials
Spinal muscular atrophy10 works · 8 trials
Irritable bowel syndrome9 works · 5 trials
Polycystic kidney disease8 works · 6 trials
Psoriatic arthritis7 works · 10 trials
Lewy body dementia6 works · 5 trials
Haemophilia6 works · 11 trials
Barrett's oesophagus5 works · 1 trial
Duchenne muscular dystrophy5 works · 17 trials
Retinitis pigmentosa5 works · 0 trials
Gastroparesis5 works · 3 trials
Charcot-Marie-Tooth disease4 works · 1 trial

Institution data: ROR 0424bsv16 (CC0-1.0)Updated 12 Nov 2026

Report an error